Table 2.
Summary of main studies on 18F-FDG PET/CT for response assessment to targeted therapy in BRAF-mutated MM.
| Authors | Year | Clinical Setting | N. of Patients | Applied Criteria | Comments |
|---|---|---|---|---|---|
| McArthur et al. [35] | 2012 | Part of a phase I clinical trial | n = 31 | EORTC | 18F-FDG PET/CT can be applied to assess response to vemurafenib; metabolic response is correlated with a trend towards a longer survival. |
| Carlino et al. [38] | 2013 | Part of a phase I clinical trial | n = 23 | EORTC | Metabolic response to BRAF-inhibitor, categorized as homogeneous or heterogeneous through PET/CT, correlated with time-to-progression in patients with BRAF-mutated MM treated with dabrafenib. |
| Schmitt et al. [39] | 2016 | Retrospective, Single-center |
n = 24 | EORTC | In patients undergoing combined anti BRAF/MEK therapy, change in SUVmax for the least responsive site of disease resulted associated with progression free survival. |
| Annovazzi et al. [40]. | 2021 | Retrospective, Single-center |
n = 57 | EORTC | Baseline MTV and complete metabolic response during BRAF/MEK therapy are predictors of OS in BRAF-mutated melanoma submitted to targeted therapy. |